摘要
①目的 探讨恶性肿瘤病人血清可溶性Fas(sFas)和可溶性白细胞介素2 受体(sIL- 2R)的表达水平。②方法 应用ELISA法测定了52例恶性肿瘤病人和20 例正常对照者血清中sFas和sIL- 2R的表达水平。③结果 肿瘤病人血清可溶性Fas表达水平明显高于正常对照组且与肿瘤种类无关。肿瘤病人血清sIL -2R水平明显高于正常对照组,与其他恶性肿瘤相比,肝癌病人血清sIL -2R增高明显。肿瘤病人血清可溶性Fas和sIL- 2R水平呈正相关。④结论 肿瘤病人血清可溶性Fas和sIL -2R表达水平明显升高,为揭示肿瘤发生、发展和逃避免疫监视提供了一个可能的机制。
Objective To study the levels of sFas and sIL-2R in serum of patients with malignant tumors. Methods The sFas and sIL 2R were measured by ELISA in 52 malignant tumor patients and 20 normal controls. Results The sFas levels were significantly higher in patients with tumors than that in the controls, which occurred in all kinds of tumor. The levels of sIL-2R in tumor patients were also significantly higher than that in the controls. The levels of sIL-2R in patients with hepatocellular carcinoma were higher than that with other tumors. There was a positive correlation between sFas and sIL-2R levels in the patients. Conclusion The serum sFas and sIL-2R levels increase significantly in tumor patients, which may explain the genesis of tumor and the mechanism of tumor cells escaping from immunosurveillance.
出处
《齐鲁医学杂志》
2005年第2期109-111,共3页
Medical Journal of Qilu
